Management of Radiation-Induced Cystitis

Pathophysiology and Clinical Presentation

• Radiation-induced cystitis results from damage to bladder vasculature and vascular endothelial cells, leading to symptoms such as dysuria, urinary frequency, nocturia, hesitancy, infection, discomfort, and hematuria 1
• Acute symptoms typically occur after a dose of 20 Gy to the bladder and subside 2-3 weeks after treatment completion 2
• Chronic symptoms can develop with a latency period of 1-25 years and are the result of progressive vascular damage 3

Risk Factors

• History of abdominal surgery, pelvic inflammatory disease, hypertension, diabetes mellitus, and smoking increase the risk of late genitourinary toxicity 2
• Older age significantly impacts incontinence risk due to potentially higher bladder neck doses 2
• Obesity and overweight are risk factors for urinary incontinence and frequency 2

Prevention Strategies

• Different IMRT modalities may reduce the rate of acute and late high-grade urinary toxicity 4
• To reduce the incidence of severe urinary complications to at least 15%, a D2cm³ ≤ 80 Gy EQD2 should be used 1
• Dose to the bladder trigone is predictive of severe late urinary toxicity and should be minimized 4
• Adequate hydration is crucial to dilute toxic metabolites in the urine 5

Treatment Algorithm

• Initial workup should include urine analysis and urine culture to rule out infection 1
• Low-grade urinary symptoms can be managed with non-steroidal anti-inflammatory drugs, anticholinergic agents, and analgesics 1
• Botulinum toxin A injection into the detrusor muscle can be used when drug therapy is ineffective 1
• For hemorrhagic cystitis, additional options include clot evacuation, endoscopic fulguration, and bladder irrigation with various substances 1

Refractory Cases

• Surgical intervention should be evaluated in cases of refractory disease 1
• Options include percutaneous nephrostomy, ureteral stent placement, and ileal ureteral substitution 4

Follow-up Recommendations

• Clinical examination and accurate history should guide further investigation with instrumental tests for urinary tract dysfunction 1
• Bladder cystitis and bleeding typically reach peak prevalence at about 30 months, after which rates fall to baseline, indicating healing 1
• Regular monitoring of renal function is necessary, especially in patients with pre-existing renal impairment 5

Important Considerations

• Infection and primary bladder malignancy must be ruled out in patients with persistent symptoms 1
• Poor vascularity and wound healing following radiation can make surgical interventions challenging 1
• While hyperbaric oxygen therapy has shown promising results, it has practical limitations including high cost and limited availability 6
• The management of radiation-induced cystitis lacks robust guidelines, requiring a tailored approach based on symptom severity 1

Management of Radiation Cystitis

Treatment Options

• Hyperbaric oxygen therapy (HBOT) induces neo-vascularization, tissue re-oxygenation, collagen deposition, and fibroblast proliferation, with reported success rates of 60-92% for refractory cases, according to Radiologia Medica 7
• Monitor renal function regularly, especially given the risk of ureteral strictures and potential for progressive kidney damage if obstruction occurs, as noted in Radiologia Medica 7

Evidence‑Based Management of Chronic Radiation Cystitis

Initial Evaluation

• Perform urine analysis and urine culture to exclude urinary‑tract infection when assessing chronic radiation‑induced bladder symptoms. 8
• Assess renal function because ureteral strictures occur in ≈ 1–3 % of patients and may develop many years after radiation exposure. 8
• Systematically rule out primary bladder malignancy, as both malignancy and radiation cystitis can present with hematuria. 8

Conservative Medical Management (Stage 1)

• Start anticholinergic therapy (e.g., oxybutynin) to control urgency, frequency, and nocturia associated with radiation‑related irritative voiding. 8
• Add non‑steroidal anti‑inflammatory drugs to relieve dysuria and bladder discomfort. 8
• Consider phenazopyridine for additional analgesia of urinary‑tract pain. 8
• These agents can usually be tapered and stopped once symptoms improve, as acute irritative symptoms are often self‑limited. 8

Advanced Conservative Therapies (Stage 2)

• Offer intradetrusor botulinum toxin A injections for patients whose overactive‑bladder symptoms persist despite anticholinergics. 8

Hemorrhagic Cystitis Management (Stage 3)

• Initiate bladder irrigation and clot evacuation for immediate control of significant hematuria. 8
• Perform endoscopic fulguration/coagulation of bleeding telangiectasias; studies report a ≈ 75 % complete‑response rate. 8

Surgical Intervention (Stage 5)

• Reserve urinary diversion with or without cystectomy for cases that have failed all conservative and endoscopic measures. 8

Risk Stratification for Severe Disease

• Patients with comorbid conditions such as diabetes, hypertension, vascular disease, or a history of smoking have a higher likelihood of requiring hospitalization or invasive therapy. 8

Monitoring and Follow‑Up

• Recognize that hemorrhagic cystitis typically peaks around 30 months after radiation, but symptoms may emerge anywhere from 1 to 25 years post‑treatment. 8
• Conduct regular renal‑function monitoring to detect ureteral strictures early and prevent secondary complications. 8
• Systematically assess quality‑of‑life impacts, as bladder dysfunction markedly affects daily activities and may necessitate therapy escalation. 8

Epidemiology & Outcomes

• Approximately 5–9 % of patients receiving pelvic radiotherapy develop chronic hemorrhagic cystitis. 8
• Up to 10 % of affected individuals ultimately require salvage cystectomy despite exhaustive conservative management. 8

Pharmacologic Management of Radiation‑Induced Cystitis

Anticholinergic Therapy

• The 2024 Italian Association of Radiotherapy and Clinical Oncology (AIRO) guidelines recommend oxybutynin as the first‑line anticholinergic for radiation‑related urinary frequency, urgency, nocturia, and hesitancy【9】【10】【11】.

NSA‑ID Therapy

• NSAIDs are advised to alleviate dysuria and bladder discomfort in radiation cystitis, with common choices such as ibuprofen 400–600 mg three times daily or naproxen 250–500 mg twice daily, dose‑adjusted for renal function and gastrointestinal risk【9】【10】.

Diagnostic Evaluation Before Treatment

• Perform urine analysis and culture to rule out urinary‑tract infection, which must be treated before attributing symptoms solely to radiation cystitis【9】.
• Exclude bladder malignancy in patients with persistent hematuria or new‑onset symptoms, as both conditions can present similarly【9】.

First‑Line Medical Management

• Initiate oxybutynin plus an NSAID as the initial therapy for low‑grade urinary symptoms (urgency, frequency, dysuria) caused by radiation exposure【9】【10】【11】.
• These agents are generally self‑limited; symptoms often improve spontaneously, allowing discontinuation once control is achieved【9】.

Management of Refractory Symptoms

• If urinary symptoms persist after 4–6 weeks of anticholinergic therapy, consider intravesical botulinum toxin A (100–200 U) injection into the detrusor muscle【9】【10】【11】.
• Botulinum toxin A is appropriate when drug therapy fails to control overactive‑bladder manifestations【9】.

Management of Hemorrhagic Cystitis

• For radiation‑induced hematuria, escalation to hydration, clot evacuation, endoscopic fulguration, and bladder irrigation is recommended【9】【10】【11】.

Additional Clinical Considerations

• Do not assume all urinary complaints are radiation‑related; urinary‑tract infection is common in this population and requires targeted antibiotic therapy【9】.
• Assess renal function before and during NSAID use because patients are at increased risk for ureteral strictures and renal impairment【9】.
• Chronic radiation‑induced bladder symptoms may appear 1–25 years after treatment, with cystitis and bleeding often peaking around 30 months before gradually improving【9】.
• Approximately 50 % of individuals receiving pelvic radiation develop urinary symptoms, underscoring the prevalence of this complication【10】【11】.

Evidence‑Based Findings on Radiation‑Induced Hemorrhagic Cystitis

Pathophysiology

• Radiation‑damaged bladder tissue exhibits poor vascularity and impaired healing, increasing the risk of bladder perforation during aggressive manipulation. 12

Epidemiology

• In patients with chronic radiation cystitis, symptom onset most commonly peaks approximately 30 months after radiation therapy, but cases may appear anywhere from 1 to 25 years post‑exposure. 12

Morbidity and Mortality

• Among this population, about 67 % require emergency urinary diversion (e.g., percutaneous nephrostomy), and mortality rates of roughly 22 % have been reported in severe, refractory cases despite aggressive treatment. 12

Adjunctive Management During Continuous Bladder Irrigation

• Aggressive intravenous hydration at 150–200 mL per hour is recommended to dilute urine and lessen clot formation during continuous bladder irrigation. 12